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There is urgent need for the development of mechanistically different and less side-effect
prone antipsychotic compounds. The endocannabinoid system has been suggested to
represent a potential new target in this indication. While the chronic use of cannabis
itself has been considered a risk factor contributing to the development of schizophrenia,
triggered by the phytocannabinoid delta-9-tetrahydrocannabinol ( 91 -THC), cannabidiol,
the second most important phytocannabinoid, appears to have no psychotomimetic
potential. Although, results from animal studies are inconsistent to a certain extent
and seem to depend on behavioral paradigms, treatment duration and experimental
conditions applied, cannabidiol has shown antipsychotic properties in both rodents and
rhesus monkeys. After some individual treatment attempts, the first randomized, double-
blind controlled clinical trial demonstrated that in acute schizophrenia cannabidiol exerts
antipsychotic properties comparable to the antipsychotic drug amisulpride while being
accompanied by a superior, placebo-like side effect profile. As the clinical improvement
by cannabidiol was significantly associated with elevated anandamide levels, it appears
likely that its antipsychotic action is based on mechanisms associated with increased
anandamide concentrations. Although, a plethora of mechanisms of action has been
suggested, their potential relevance for the antipsychotic effects of cannabidiol still
needs to be investigated. The clarification of these mechanisms as well as the
establishment of cannabidiol’s antipsychotic efficacy and its hopefully benign side-effect
profile remains the subject of a number of previously started clinical trials.
Keywords: schizophrenia, psychosis, animal models, clinical trials, CBD
INTRODUCTION
Cannabis sativa has been known and used by humans for several 1000 years and the knowledge
that it contains an intoxicating principle dates back to 1000 to 1500 B.C. (Adams, 1942). The
two major compounds of cannabis – delta-9-tetrahydrocannabinol (19-THC) and cannabidiol –
have been chemically identified in the 1940th (Adams et al., 1940a,b,c; Adams, 1942; Todd, 1946).
Two decades later, remaining uncertainties regarding the exact position of double bonds were
eliminated as new imaging techniques like NMR spectroscopy and X-ray structure determination
became available (Mechoulam and Shvo, 1963; Gaoni and Mechoulam, 1964; Jones et al., 1977).
Along with its chemical identification, 19-THC has been identified as the major pro-
psychotic compound of Cannabis sativa (Adams and Baker, 1940; Adams et al., 1940b; Allentuck
and Bowman, 1942; Wollner et al., 1942; Mechoulam et al., 1970). However, the underlying
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neurobiological principles remained conjectural until it was
observed that cannabinoid drugs inhibit adenylate cyclase activity
in neuroblastoma cells (Howlett, 1984), and the subsequent
discovery of the G-protein coupled type 1 cannabinoid receptor
(CB1R) (Devane et al., 1988; Matsuda et al., 1990). A few
years later, the type 2 cannabinoid receptor (CB2R) (Munro
et al., 1993) as well as the two major endogenous ligands
to cannabinoid receptors – anandamide (Devane et al., 1992)
and 2-arachidonoyl-sn-glycerol (Mechoulam et al., 1995; Stella
et al., 1997) – were discovered. The architecture of the
endocannabinoid system (ECS) – including endocannabinoids,
cannabinoid receptors as well as synthesizing and degrading
enzymes – has been vividly summarized and illustrated in recent
reviews by Lutz et al. (2015) and Lu and Mackie (2016).
Studies indicating that cannabis abuse might be a stressor for
psychotic relapse and exacerbation of schizophrenic symptoms as
well as the observation that 19-THC induced schizophrenia-like
neuropsychological and psychopathological alterations in healthy
volunteers, led to the hypothesis that a dysfunctional ECS is
involved in the etiology of psychoses (Emrich et al., 1997). In
the meantime, several studies reported diverse acute 19-THC
effects in healthy participants and schizophrenic patients, thereby
confirming the ECS hypothesis (Leweke et al., 1999, 2000;
D’Souza et al., 2004, 2005; Koethe et al., 2006; Bhattacharyya et al.,
2009; Fusar-Poli et al., 2009; Koethe et al., 2009; Mason et al.,
2009; Sherif et al., 2016). In addition, several epidemiological
studies (for review see, Gage et al., 2016) substantiated the
view that cannabis use has to be considered an important
environmental risk factor for the development of schizophrenia
in vulnerable individuals. However, the actual lifetime risk seems
to be influenced by the dose (Zammit et al., 2002; Moore
et al., 2007) and frequency of cannabis consumption (Di Forti
et al., 2009), the potency of consumed cannabis preparations
(Di Forti et al., 2009, 2014) and age of onset (Arseneault et al.,
2002).
While a dysfunctional ECS seems to contribute to the
pathophysiology of schizophrenia, the endocannabinoid
anandamide is considered to have protective effects by
counteracting neurotransmitter imbalances (Leweke, 2012).
Therefore, it has been suggested that modulating the ECS might
be a new, promising pharmacological target for schizophrenia.
To date, two main approaches targeting the ECS have
been systematically studied in humans: first, trials using CB1R
antagonists to treat both psychotic and cognitive symptoms
of schizophrenia, and, second, trials using the second most
important phytocannabinoid cannabidiol (Leweke et al., 2016).
In addition, a single clinical case series on dronabinol (19-THC)
in treatment-refractory severe chronic schizophrenia has been
conducted (Schwarcz et al., 2009).
In contrast to 19-THC, cannabidiol appears to have no
psychotomimetic potential, but shows antipsychotic effects in
rodents and humans. Thus, this review focuses on (1) preclinical
studies investigating cannabidiol as a potential antipsychotic in
animal models of aspects of schizophrenia, (2) clinical evidence
for its antipsychotic action, and, (3) potential mechanisms of
action and their potential relevance for the antipsychotic effects
of cannabidiol.
METHODS
We conducted a PubMed search up to and including June 28,
2016, using the search terms cannabidiol AND (antipsychotic
OR schizophrenia OR psychosis). Identified references were
scanned for clinical trials with schizophrenic patients as well as
studies with animal models of aspects of schizophrenia, analyzing
the effects of cannabidiol on negative symptoms and cognitive
deficits. Studies restricted to analysis of locomotor activity or
anxiety were not considered. In addition, we used the search term
cannabidiol AND targets to scan for reports on the possible mode
of action.
ANTIPSYCHOTIC POTENTIAL OF
CANNABIDIOL: INSIGHTS FROM
PRECLINICAL STUDIES
Schizophrenia is characterized by heterogeneous symptoms that
can be grouped into three main symptom categories: (1) positive
symptoms (delusions, thought disorder, hallucinations), (2)
negative symptoms (anhedonia, blunted affect, social withdrawal)
and (3) cognitive impairment (sensory information processing,
attention, working memory, executive functions) (Freedman,
2003; Wong and Van Tol, 2003). These main symptoms are
often accompanied by more unspecific symptoms like anxiety
(Freedman, 2003).
Although psychotic symptoms are human specific to a large
extent, animal models are able to provide insight into certain
aspects of schizophrenia, including negative symptoms [e.g.,
inadequate social behavior/social withdrawal, sensorimotor
gating deficits as measured by prepulse inhibition (PPI)],
cognitive impairments (e.g., working memory deficits) or
anxiety. Thus, these animal models for aspects of schizophrenia
can be used to investigate the antipsychotic potential of
new drugs like cannabidiol on negative and cognitive
symptoms. As available antipsychotics do not sufficiently
ameliorate negative symptoms and cognitive impairments
(Hanson et al., 2010), these studies can make an important
contribution.
Schizophrenia is not only characterized by a heterogeneous
combination of symptoms but also by a heterogeneous etiology
(Cannon and Jones, 1996; Brown, 2011; Kahn et al., 2015). This
led to the development of animal models based on different
etiological factors of schizophrenia. In the following, the concepts
of animal models used to study the effects of cannabidiol are
summarized in brief.
As mentioned above, cannabis use is regarded as one
important risk factor for the development of schizophrenia.
Hence, animal models of early cannabis exposure are used to
investigate the long-lasting behavioral consequences of cannabis
use and to clarify the underlying cellular mechanisms (Rubino
and Parolaro, 2016). However, based on the observation that
cannabis preparations or single cannabinoids like 19-THC
induce psychotic-like symptoms in healthy volunteers (for review
see Sherif et al., 2016), acute cannabinoid administration is also
used to mimic schizophrenia-like symptoms in rodents.
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Furthermore, based on the hypothesis that disrupted
glutamatergic neurotransmission contributes to the development
of schizophrenia (Kim et al., 1980), pharmacological and genetic
glutamatergic models have been used in cannabidiol research.
Since this dysfunction is characterized by hypofunctional
N-methyl-D-aspartic acid (NMDA) receptors (for review see
Snyder and Gao, 2013), for example, NMDA receptor antagonists
like MK-801 are administered to mimic schizophrenic-like
symptoms in rodents. The genetic model is based on neuregulin
1, a susceptibility gene for schizophrenia (Stefansson et al.,
2002). Neuregulin 1 is involved in neuronal migration, influences
myelination and regulates expression of NMDA, γ-aminobuytric
acid receptor A (GABAA) as well as acetylcholin receptor
subunits (for review see Corfas et al., 2004). Heterozygous
transmembrane Neuregulin 1 mutant mice (Nrg1 TM HET)
seem to have fewer functional NMDA receptors (Stefansson
et al., 2002), a region-specific alteration of NMDA receptor
expression as well as decreased dopamine D2 receptor binding in
the striatum (Newell et al., 2013). Interestingly, the CB1 receptor
density is comparable to the density in wild type animals except
for a slight increase within the striatum of Nrg1 TM HET (Newell
et al., 2013).
The spontaneously hypertensive rat (SHR) strain has also
been suggested as a model for aspects of schizophrenia. These
rats show impaired social interaction (Calzavara et al., 2011;
Almeida et al., 2014) and reduced PPI (Levin et al., 2011,
2014) as compared to Wistar rats. In addition, antipsychotic
drugs reduced abnormalities in contextual fear conditioning
(Calzavara et al., 2009), social interaction (Calzavara et al.,
2011) as well as PPI (Levin et al., 2011). Nevertheless,
other studies observed an increased PPI compared to Sprague
Dawely rats (van den Buuse, 2004) or an increased social
interaction behavior toward Wistar-Kyoto rats (Hopkins et al.,
2009).
Effects of Cannabidiol on Social
Behavior
Social withdrawal is a key negative symptom of schizophrenia.
Thus, several studies investigated the effects of cannabidiol
on social behavior in different rodent animal models for
schizophrenia (Table 1).
Cannabidiol (dosage range: 1–50 mg/kg) itself seems to have
no effect on social interaction of untreated Sprague Dawley
(Malone et al., 2009; Gururajan et al., 2012), Wistar rats (van
Ree et al., 1984; Deiana et al., 2015), C57BL/6JArc mice (Long
et al., 2010; Gomes et al., 2015b), and wild type-like littermates
of Nrg1 TM HET mice (Long et al., 2012). However, in Wistar
rats 1 mg/kg cannabidiol increased social interaction behavior,
whereas higher dosages (5, 15, 30, 60 mg/kg) had no effect
(Almeida et al., 2013). In addition, impaired social memory
was observed in Wistar rats (Deiana et al., 2015) after acute
cannabidiol administration (12 and 30 mg/kg, but not 5 mg/kg).
The majority of studies reported that cannabidiol was able to
attenuate or reverse induced altered social behavior. Pretreatment
with 20 mg/kg cannabidiol reversed the effects of 1 mg/kg
19-THC (Malone et al., 2009), while 3 mg/kg cannabidiol
inhibited the effects on social investigative behavior of acute MK-
801 treatment in a modified social interaction task, increasing it
significantly beyond control level (Gururajan et al., 2012). This is
in line with the previous finding of the group that cannabidiol (3,
10 mg/kg) partially inhibited MK-801-induced social withdrawal
in a classical social interaction paradigm (Gururajan et al.,
2011). In mice, pretreatment with 60 mg/kg cannabidiol was
found to reverse impaired social interaction induced by chronic
MK-801 treatment, while a lower cannabidiol dose (30 mg/kg)
attenuated the effects of MK-801 only by trend (Gomes et al.,
2015b). As the antipsychotic clozapine also inhibited MK-801
effects on social investigative behavior, it has been suggested
that cannabidiol might also be effective in schizophrenia patients
showing inadequate social behaviors (Gururajan et al., 2012;
Gomes et al., 2015b). However, cannabidiol did not reverse the
social recognition impairments induced by an acute low-dose
injection of MK-801 in Wistar rats. Furthermore, cannabidiol was
not able to elevate the decreased social interaction of SHR rats
(Almeida et al., 2013).
Although, Nrg1 TM HET mutant mice showed similar social
behavior compared to their wild type-like littermates (Long
et al., 2012), chronic cannabidiol treatment (50 mg/kg, 21 days)
increased social interaction as well as specific social behaviors
like nosing and anogenital sniffing in mutant mice but not in
wild type mice. A higher cannabidiol dose (100 mg/kg) solely
increased anogenital-sniffing duration in mutant mice, while
lower concentrations (1 mg/kg) led only to increasing nosing
frequencies.
Taken together, cannabidiol showed antipsychotic properties
in glutamatergic animal models as well as in a model targeting
the ECS, whereas it has been ineffective in SHR rats.
Effects of Cannabidiol on Prepulse
Inhibition
Prepulse inhibition of the acoustic startle response is a
neuropsychological process during which a weak sensory
stimulus – prepulse – attenuates the motor response to a
subsequent strong startling stimulus (Rohleder et al., 2016). Since
PPI impairments are observed in schizophrenia patients and PPI
can be reliably assessed in both animals and humans, it has
been used as behavioral measure of aspects of schizophrenia.
Unfortunately, results from rodent studies analyzing the effects
of cannabidiol on PPI and acoustic startle response in animal
models of schizophrenia and untreated control rodents are
inconsistent to a certain extent (Table 2).
The effects of cannabidiol on startle amplitude and PPI of
healthy rodents seem to be not only dose- but also strain- and
species-dependent. In male Swiss mice, cannabidiol (15, 30, or
60 mg/kg) did not affect PPI or startle amplitude (Pedrazzi
et al., 2015). On the other hand, Long et al. (2006) reported
that C57BL/6JArc mice acutely treated with cannabidiol (1
and 15, but not 5 mg/kg) showed increased startle amplitudes
while PPI remained unaffected. In contrast, in wild type-like
littermates of Nrg1 TM HET mice, acute treatment with low
concentrations of cannabidiol (1 and 50 mg/kg) as well as chronic
cannabidiol treatment (1, 50, 100 mg/kg; 21 days) had no effect
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TABLE 1 | Animal studies evaluating the effects of cannabidiol (CBD) on social behavior.
Animal model Treatment regimen and test
procedure
Effective dose [/kg] Reference
Spontaneously hypertensive rats (SHR) 1, 5, 15, 30, or 60 mg/kg CBD, i.p.
injection 30 min prior to social
interaction test
– Almeida et al., 2013
MK-801 (acute, 0.3 or 0.6 mg/kg), male
Sprague Dawley rats
1 or 3 mg/kg CBD, i.p. injection 20 min
prior to MK-801 administration. Social
interaction test started 20 min after the
last injection
3, 10 (partially) Gururajan et al., 2011
MK-801 (acute, 0.3 mg/kg), male
Sprague Dawley rats
1 or 3 mg/kg CBD, i.p. injection 20 min
prior to MK-801 administration.
A modified social interaction test
started 20 min after the last injection
3 Gururajan et al., 2012
MK-801 (chronic: 1 mg/kg, 28 days),
male C57BL/6J mice
30 or 60 mg/kg CBD, i.p. injection
30 min prior to social interaction test
60 Gomes et al., 2015b
MK-801 (acute, 0.08 mg/kg), male
Wistar rats
5, 12, or 30 mg/kg CBD, i.p. injection
30 min prior to MK-801 administration.
Social interaction/recognition test
started 30 min after the last injection
– Deiana et al., 2015
Male Nrg1 TM HET mice Chronic treatment with 1, 50, or
100 mg/kg CBD over 3 weeks
50 (partially 1 and 100) Long et al., 2012
19-THC (1 mg/kg), male Sprague
Dawley rats
5 or 20 mg/kg CBD, i.p. injection
20 min prior to 19-THC administration.
Social interaction test started 20 min
after the last injection
20 Malone et al., 2009
TABLE 2 | Animal studies evaluating the effects of cannabidiol (CBD) on prepulse inhibition (PPI).
Animal model Treatment regimen and test
procedure
Effective dose [mg/kg] Reference
Spontaneously hypertensive rats (SHR) 15, 30, or 60 mg/kg CBD, i.p. 30 min
prior to PPI paradigm
30 Levin et al., 2014
MK-801 (acute, 0.3 or 0.6 mg/kg), male
Sprague Dawley rats
3, 10, or 30 mg/kg CBD, i.p. injection
20 min prior to MK-801 administration.
PPI paradigm started 20 min after the
last injection
– Gururajan et al., 2011
MK-801 (chronic: 1 mg/kg, 28 days),
male C57BL/6J mice
30 or 60 mg/kg CBD, i.p. treatment
began on 6th day of MK-801
administration. PPI paradigm was
conducted on day 29
30, 60 Gomes et al., 2015a
MK-801 (acute, 1 mg/kg), male
C57BL/6J mice
5 mg/kg CBD, i.p. injection 20 min prior
to MK-801 administration. PPI
paradigm started 5 min after the last
injection
5 Long et al., 2006
Male Nrg1 TM HET mice 1, 50, or 100 mg/kg CBD, i.p. over
21 days. PPI paradigm was done
30–45 min after the first injection and
on day 21
100 (acute) Long et al., 2012
Amphetamine (acute, 10 mg/kg) male
Swiss mice
15, 30, or 60 mg/kg CBD, i.p. 30 min
prior to amphetamine injection. PPI
paradigm started 30 min after the last
injection
15, 30, 60 Pedrazzi et al., 2015
on startle amplitude and PPI, but acute administration of a high
cannabidiol dosage (100 mg/kg) resulted in an increased startle
amplitude (Long et al., 2012).
Such heterogeneous results were also observed in healthy rats.
In Sprague Dawley rats, cannabidiol reduced startle amplitude (3
and 10 but not 30 mg/kg) and PPI (10 mg/kg only) in a dose-
dependent manner (Gururajan et al., 2011), whereas the startle
amplitude of Wistar rats was not influenced by acute cannabidiol
(15, 30, 60 mg/kg) treatment, while higher dosages of cannabidiol
(30, 60 mg/kg) seemed to increase PPI (Levin et al., 2014).
Interestingly, animals with transmembrane Neuregulin 1
mutation, representing a genetic glutamatergic schizophrenia
model, showed similar startle amplitude and PPI compared to
their wild type like littermates. However, acute administration of
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100 mg/kg cannabidiol increased not only the startle amplitude as
observed in wild type like littermates, but also PPI. On the other
hand, chronic cannabidiol treatment (1, 50, 100 mg/kg; 21 days)
had no effect on startle amplitude and PPI in Nrg1 TM HET or
their wild type like littermates (Long et al., 2012).
Pharmacological studies mimicking glutamatergic deficits
of schizophrenia revealed that pretreatment with cannabidiol
(5 mg/kg) reversed PPI disruption in C57BL/6JArc mice (Long
et al., 2006). In addition, chronic cannabidiol treatment (30 or
60 mg/kg) attenuated PPI impairments induced by chronic MK-
801 administration in C57BL/6J mice (Gomes et al., 2015a).
While cannabidiol seems to be efficacious in treating PPI
impairments in mice, pretreatment with cannabidiol had no
effect on PPI deficits induced by acute MK-801-injection in
Sprague Dawley rats (Gururajan et al., 2011).
However, acute cannabidiol treatment also reversed PPI
deficits in two other animal models of aspects of schizophrenia.
First, cannabidiol (30 mg/kg) reversed PPI deficit of SHR
rats but had no effects on their reduced startle amplitude
(Levin et al., 2014). Second, cannabidiol (15, 30, or 60 mg/kg)
attenuated the amphetamine-disruptive effects on PPI in male
Swiss mice (Pedrazzi et al., 2015). Interestingly, the inhibition
of anandamide hydrolysis by URB597 [selective fatty acid
amide hydrolase (FAAH) inhibitor] had the same effect.
Hence, the authors suggested that an increase of anandamide
availability might be involved in the beneficial effects of
cannabidiol.
In a nutshell, various studies showed that cannabidiol partially
affected startle amplitude and PPI in healthy animals, while it
had no effects in rats treated with MK-801, but reversed the PPI
disruptive effects of MK-801 and amphetamine in mice as well as
the PPI deficit of SHR rats.
These discrepancies, observed in both healthy wild type
animals and animal models for aspects of schizophrenia,
might be related to the different species/strain or experimental
conditions applied. Therefore, more studies clarifying the
potential antipsychotic effect of cannabidiol with regard to this
specific behavioral deficit are desirable.
Effect of Cannabidiol on Working
Memory
Various paradigms are available to test cognitive performance
in animals. Two studies investigating the effects of cannabidiol
on cognitive performance in 19-THC- or MK-801-treated
animals, respectively, used paradigms based on object and/or
spatial recognition. In addition, two further studies investigated
the effects of cannabidiol-rich cannabis extracts in a spatial
recognition task (Table 3).
The visuospatial Paired Associates Learning task (vsPAL)
and the Self-Ordered Spatial Search (SOSS) task belong to the
category of spatial recognition tasks that are frequently used in
non-human primates. In rhesus monkeys, acute intramuscular
19-THC administration (0.2 and 0.5 mg/kg) impaired overall
trial completion accuracy and percent completed trials in the
vsPAL with increasing trial-difficulty as well as trial completion
accuracy in the SOSS task (Wright et al., 2013). Cannabidiol
itself had no effect on cognitive performance. Interestingly,
co-treatment with cannabidiol reversed the effects of 19-
THC on vsPAL, but did not affect 19-THC-induced SOSS
deficits.
These results are in line with a study assessing the effects
of cannabidiol on novel object recognition (NOR) impairments
in mice. The NOR task is often used in rodents and partially
resembles vsPAL. While in vsPAL a familiar object and its former
position has to be identified, NOR evaluates whether the animal
recognizes a new unfamiliar object, as rodents tend to explore
new objects more intensively than familiar ones. Cannabidiol
(30 or 60 mg/kg) significantly reversed the NOR performance
impairments observed in male C57BL/6J mice chronically treated
with MK-801, but had no effect per se (Gomes et al., 2015b).
Furthermore, Fadda et al. (2004, 2006) investigated the effects
of cannabidiol-rich cannabis extracts in a water maze based
delayed-matching-to-position task (DMTP). In the first trial,
animals were placed onto a platform. In the second trial animals
were released into the water and had to find the platform again.
Cannabidiol-rich cannabis extracts did not affect the spatial
working memory of rats, although these extracts also contained
19-THC. In particular the highest dose of 50 mg/kg cannabidiol-
rich extracts contained nearly 4 mg/kg 19-THC, a dose that was
sufficient to impair the working memory when given alone. Thus,
the authors concluded that cannabidiol is able to antagonize
the cognitive impairment. However, the cannabidiol-rich extracts
did not reverse memory deficits when administered concurrently
with the 19-THC-rich cannabis extracts. Therefore, it has been
suggested, that the cannabidiol/19-THC ratio was not high
enough to be effective (Fadda et al., 2004).
Interestingly, cannabidiol-rich extracts (5 and 10 mg/kg) were
also unable to reverse working memory deficits induced by MK-
801 in rats (Fadda et al., 2006). It might be that the cannabidiol
dosage had simply been too low, as higher concentrations (30 or
60 mg/kg) had been shown to be effective in mice (Gomes et al.,
2015b). However, even higher dosages of cannabidiol may not
reverse working memory deficits induced by MK-801 in rats due
to interspecies differences.
Overall, the limited data available seem to suggest that
cannabidiol has potential in ameliorating not only negative
symptoms but also cognitive functions. However, as task-selective
differences were observed, its effectiveness might be restricted to
certain aspects of cognitive functions. Therefore, further studies
analyzing the effects of cannabidiol on various cognitive aspects
are called for.
ANTIPSYCHOTIC POTENTIAL OF
CANNABIDIOL: EVIDENCE FROM
CLINICAL STUDIES
The results of the first individual treatment attempt with
cannabidiol were reported in Zuardi et al. (1995). Daily
administration of up to 1500 mg/day over 4 weeks resulted in
decreased scores on the Brief Psychiatric Rating Scale (BPRS) and
Interactive Observation Scale for Psychiatric Inpatients (IOSPI),
indicating an overall improvement of psychotic symptoms.
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TABLE 3 | Animal studies evaluating the effects of cannabidiol (CBD) on working memory.
Animal model Treatment regimen and test procedure Effective dose
[mg/kg]
Reference
MK-801 (chronic: 1 mg/kg, 28 days),
male C57BL/6J mice
30 or 60 mg/kg CBD, i.p. injection 30 min prior to novel
object recognition test
30, 60 Gomes et al., 2015b
19-THC (0.2, 0.5 mg/kg i.m.), male
adults rhesus monkeys
0.5 mg/kg CBD, i.m. concurrently with 19-THC
administration. Visuospatial Paired Associates Learning
task and Self-Ordered Spatial Search started 30 min after
the injections
0.5 (task selective) Wright et al., 2013
19-THC-rich and CBD-rich cannabis
extracts, male, adult Lister rats
CBD-rich cannabis extracts (0.5, 5, 10, or 50 mg/kg CBD
and up to 4 mg/kg 19-THC), i.p. 30 min prior to Delayed
Matching to Sample task. In addition, CBD-rich cannabis
extracts were simultaneously injected with 19-THC-rich
cannabis extract injection
50 (as it contained
nearly 4 mg/kg
19-THC
Fadda et al., 2004
MK-801 (0.1 mg/kg, acute), male, adult
Lister rats
CBD-rich cannabis extracts (5 or 10 mg/kg CBD), i.p.
concurrently with MK-801 injection, 30 min prior to Delayed
Matching to Sample task. In addition, CBD-rich cannabis
extracts were simultaneously injected with 19-THC-rich
cannabis extract injection
– Fadda et al., 2006
Interestingly, the clinical improvement was not increased
by additional treatment with haloperidol, a first generation
antipsychotic. Nearly 10 years later, Zuardi et al. (2006)
published a small case series of three patients. They were treated
with increasing doses of cannabidiol (maximum 1280 mg/kg)
over 30 days. Importantly, one of these patients showed a
slight improvement of both positive and negative symptoms.
Interestingly, no side effects were reported in patients treated
with cannabidiol. The first controlled, randomized, double-
blind clinical trial was conducted by Leweke et al. (2012).
During this 4-week trial 42 schizophrenic patients received
either cannabidiol (600–800 mg/day) or amisulpride (600–
800 mg/day) – a highly effective second generation antipsychotic,
selectively antagonizing D2/3 receptors (Leucht et al., 2002).
Both drugs resulted in significant clinical improvement of
both positive and negative symptoms of psychosis. The efficacy
of cannabidiol was comparable to that of amisulpride, but,
importantly, cannabidiol revealed a superior side effect profile
when compared to amisulpride. In particular, cannabidiol did
not induce prolactin increase, weight gain, or extrapyramidal
symptoms. Interestingly, in patients randomly allocated to
cannabidiol treatment, the reduction of psychotic symptoms was
significantly associated with an increase of anandamide levels
in serum. This was exclusive for the cannabidiol treatment
group and is in support for the hypothesis that cannabidiol’s
antipsychotic effect is at least in part mediated via anandamide
and potentially related to a block of its metabolization or uptake.
As reviewed in Leweke et al. (2016), four additional clinical
trials with schizophrenic patients have been initiated so far.
Although to date data have not been published in a peer
reviewed process, the sponsor of one recent clinical trial
investigating the antipsychotic effects of cannabidiol (GW42003,
1000 mg/day) as add-on medication in 88 patients suffering
from schizophrenia or related disorders (e.g., schizoaffective or
schizophrenia-like disorder) over a period of 6 weeks, announced
that cannabidiol was consistently superior to placebo with regard
to psychopathology while at the same time showing no relevant
side-effect profile (GW Pharmaceuticals plc, 2015).
While cannabidiol seems to develop antipsychotic properties
during at least 4 weeks of treatment, acute administration
of cannabidiol (300 or 600 mg/kg) did not affect selective
attention studied in 28 schizophrenic outpatients (regularly
treated with antipsychotics) using the Stroop Color Word Test
(Hallak et al., 2010). However, there also were no side effects
reported.
Although, only few data on the antipsychotic potential in
schizophrenic patients are currently available (summarized in
Table 4), they consistently indicate a promising efficacy and
favorable side-effect profile of cannabidiol. However, large-scale
clinical trials are still needed to evaluate the long-term efficacy
and safety of this putative new antipsychotic.
CANNABIDIOL: POTENTIAL
MECHANISM OF ACTION
The mode of action of cannabidiol is still not fully understood,
although a plethora of possible mechanisms have been proposed.
Cannabidiol and 19-THC are the most important
phytocannabinoids in the cannabis plant. Therefore, it has
been hypothesized that both compounds might have the same
molecular target, the cannabinoid receptors. However, several
binding studies showed that cannabidiol has no significant
affinity at CB1R and CB2R (Devane et al., 1988; Showalter
et al., 1996; Thomas et al., 1998; Bisogno et al., 2001; Jones
et al., 2010). In addition, most efficacy studies found no explicit
receptor response (Matsuda et al., 1990; Petitet et al., 1998;
Breivogel et al., 2001; Jones et al., 2010). In fact, it has been
reported that cannabidiol acts as an antagonist of CB1R agonists
such as WIN-55212 and CP-55940 (Petitet et al., 1998; Pertwee
et al., 2002; Thomas et al., 2007). As cannabidiol also inhibited
internalization of CB1R (Laprairie et al., 2014), it has been
hypothesized that the observed antagonistic activity might be
based on negative allosteric modulation of CB1R rather than on
orthosteric binding (Laprairie et al., 2015). Consistent with these
findings, Laprairie et al. (2015) provided evidence that in vitro
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cannabidiol behaves as a non-competitive negative allosteric
modulator of CB1R.
Owing to the observed significant association of the
antipsychotic effect of cannabidiol with an increase of
anandamide levels in serum (Leweke et al., 2012), it has
been hypothesized that cannabidiol exerts its antipsychotic
properties by moderately blocking FAAH, resulting in an
inhibition of anandamide and of related fatty acid ethanolamide
(palmitoylethanolamide and oleoylethanolamide) degradation.
In vitro, cannabidiol inhibited FAAH in mouse neuroblastoma
cell (N18TG2) membrane preparations (Bisogno et al., 2001),
mouse brain microsomes (Watanabe et al., 1996), as well as
homogenates of rat brain membranes (De Petrocellis et al.,
2011; Leweke et al., 2012). Moreover, it has been shown that
cannabidiol blocks anandamide transporters, since it inhibited
anandamide uptake by rat basophilic leukemia cells (RBL-2H3)
(Rakhshan et al., 2000; Bisogno et al., 2001; De Petrocellis et al.,
2011). So far, one possible anandamide transporter, termed
FAAH-like anandamide transporter (FLAT) has been identified
(Fu et al., 2012). As FLAT seems to be a splicing variant of the
Faah-1 gene, it may be speculated that cannabidiol binds to
similar binding sites of FAAH and FLAT proteins and is able to
inhibit both, anandamide degradation and uptake. However, it
has recently been reported that cannabidiol does not inhibit the
human FAAH enzyme, but binds to fatty acid-binding proteins
(FABPs) (Elmes et al., 2015), which seem to act as intracellular
transporters of anandamide and other N-acylethanolamines
(Kaczocha et al., 2009, 2012). Elmes et al. (2015) concluded
that cannabidiol reduces anandamide inactivation in humans
by competing with anandamide for FABPs binding. As long
as FABPs are occupied by cannabidiol, anandamide cannot be
transported to the FAAH enzyme, localized on the endoplasmic
reticulum, resulting in elevated anandamide levels.
Although, various other molecular targets have been suggested
to contribute to the antipsychotic effects of cannabidiol, their
pharmacological relevance still needs to be evaluated in clinical
trials.
On the one hand cannabidiol may facilitate 5-HT1A receptor
mediated serotonergic neurotransmission. In Chinese hamster
ovary (CHO) cells transfected with the human receptor,
cannabidiol displaced the 5-HT1A receptor agonist [3H]8-OH-
DPAT and increased [35S]GTPγS binding (Russo et al., 2005). On
the other hand, cannabidiol did not displace [3H]8-OH-DPAT
or stimulate [35S]GTPγS binding in rat brainstem membrane
preparations, while it increased the maximal efficacy of 8-OH-
DPAT at 100 nmol/L, but not at 1, 10, 31.6 nmol/L or 1 µmol/L
(Rock et al., 2012). Interestingly, in mice, the anticataleptic effect
of cannabidiol was prevented by the 5-HT1A receptor antagonist
WAY100635 (Gomes et al., 2013; Sonego et al., 2016). However, it
remains unclear, whether the improvement of negative symptoms
and cognitive deficits by cannabidiol involves 5-HT1A receptor
activation, as studies addressing this mechanism are lacking.
In addition, it has been reported that cannabidiol binds
to the peroxisome proliferator-activated receptor gamma
(PPARγ) in vitro (O’Sullivan et al., 2009; Granja et al., 2012).
PPARγ regulates the expression of genes related to lipid and
glucose homeostasis as well as inflammatory responses. Thus,
cannabidiol may ameliorate both observed disturbances of
glucose metabolism and inflammatory/immune processes in
schizophrenic patients (Holmes et al., 2006; Leza et al., 2015;
Rajasekaran et al., 2015) by PPARγ activation.
The activation of transient receptor potential vanilloid type
1 receptors (TRPV1Rs) has also been suggested as mechanism
of action, as cannabidiol stimulated TRPV1R in HEK293-cells
transiently expressing human (Bisogno et al., 2001; Ligresti
et al., 2006; De Petrocellis et al., 2011) or rat TRPV1R (Iannotti
et al., 2014). In vivo, it has been shown that pretreatment with
TRPV1R antagonist capsazepine blocked the ameliorating effect
of cannabidiol on MK-801 induced PPI decrease (Long et al.,
2006), indicating at least a partial involvement of TRPV1R
activation. However, capsazepine also blocks calcium channels
(Docherty et al., 1997) and nicotinic cholinergic receptors (Liu
and Simon, 1997), thus other mechanisms might contribute to
this effect as well. Since TRPV1Rs also mediate the perception
of spiciness, it may be expected that receptor stimulation by
systemic administration of cannabidiol result in such subjective
perceptions, given that this mechanism is relevant in humans
at the dosage used. Yet, this side effect has not been reported
TABLE 4 | Published clinical trials and case series evaluating the effects of cannabidiol in schizophrenic patients.
Design Primary efficacy
endpoint
Outcome Reference
Single case report, open-label, treatment-resistant
schizophrenia, up to 1500 mg/day CBD over 4 weeks
Psychotic symptoms
(BPRS; IOSPI)
Improvement in a treatment-resistant patient Zuardi et al., 1995
Open-label, case series (three patients), treatment-resistant
schizophrenia, up to 1280 mg/day CBD over 30 days
Psychotic symptoms
(BPRS)
One patient showed mild improvement in
positive and negative symptoms
Zuardi et al., 2006
Double-blind, active controlled acute trial, single CBD (300
or 600 mg) or placebo administration
Stroop Color Word Test
(SCWT)
No beneficial effects of single CBD
administration on cognitive performance of
schizophrenic patients
Hallak et al., 2010
Double-blind, active-controlled RCT with 42 acute
schizophrenic patients, 600–800 mg/day over 4 weeks
Psychotic symptoms
(PANSS/BPRS)
Significant clinical improvement compared to
baseline on days 14 and 28 for CBD and
amisulpride. Superior side-effect profile for CBD
compared to amisulpride
Leweke et al., 2012
BPRS, Brief Psychiatric Rating Scale; CBD, cannabidiol; IOSPI, Interactive Observation Scale for Psychiatric Inpatients; PANSS, Positive and Negative Syndrome Scale;
RCT, randomized clinical trial.
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or observed in clinical trials so far (e.g., Leweke et al., 2000,
2012). To date, evidence for a role of TRPV1R activation
in schizophrenia is lacking, but TRPV1Rs may be indirectly
involved in schizophrenia via its influence on dopaminergic
(Tzavara et al., 2006) and glutamatergic neurotransmission
(Fawley et al., 2014).
Furthermore, it has been suggested that cannabidiol targets
GPR55 and GPR18 receptors, further subtypes of transient
receptor potential receptors (TRPV2, TRPM8, TRPA1), α3
glycine receptors, adenosine receptors, µ and δ opioid receptors,
nicotinic acetylcholine receptors, enzymes of the arachidonic
acid cascade, ion channels like voltage-gated calcium channels
or mitochondrial Na+/Ca2+ exchange, nitric oxide signaling and
inflammatory cytokines (McPartland et al., 2014; Ibeas Bih et al.,
2015). To date, the antipsychotic properties of cannabidiol cannot
be directly linked to these possible targets. However, this does not
mean that these mechanisms are not relevant for other medical
conditions, e.g., epilepsy (Devinsky et al., 2014).
CONCLUSION
The antipsychotic potential of cannabidiol has been investigated
in various behavioral paradigms and different animal models
of aspects of schizophrenia. Although the results were partially
inconsistent, they indicate that cannabidiol treatment ameliorates
impairments of PPI, social interaction behavior and cognition in
rodents and rhesus monkeys. In addition, individual treatment
attempts as well as one randomized, double-blind clinical
study, demonstrated the antipsychotic potential of cannabidiol
and its superior side effect profile compared to conventional
antipsychotics. In addition, a recently conducted clinical trial
investigating cannabidiol as an add-on medication showed
promising results, although these have not yet been published
in a peer reviewed process. Obviously more clinical trials are
needed to substantiate the current findings, and in particular to
investigate long-term efficacy and safety in larger cohorts.
However, cannabidiol seems to represent a mechanistically
different and less side-effect prone antipsychotic compound
for the treatment of schizophrenia, even though the
underlying pharmacological mechanisms are still under
debate. Nevertheless, the association between increased
anandamide levels and reduced psychotic symptoms in
schizophrenic patients treated with cannabidiol, points to a
potentially new antipsychotic mechanism of action involving
anandamide.
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